According tomedia reports, the new coronavirus pandemic has led people to many “new normals”, one of which may be people began to monitor their vital signs more closely. The Apple Watch, Fitbit wristband, Omron Heartguides and various blood glucose monitors are the first wave of measures used to achieve this goal, but more comprehensive clinical-level monitoring may now become more likely.
VitalConnect recently obtained an FDA emergency license to monitor heart problems caused by treatments such as neo-coronavirus or hydroxychloroquine. It is also used to closely monitor patients who undergo certain heart valve surgery – a group that is at serious health risk situ at critical first week after discharge.
The company’s VitalPatch is understood to be a hospital-grade device that can be packaged. “From a monitoring point of view, we’ve reduced the size of the ICU to a coin-sized biosensor,” said Peter van Haur, CEO of VitalConnect. We have the ability to monitor electrocardiograms, continuous body temperature, breathing rate, activity and posture. In addition, the VitalPatch platform can extract data from blood oxygen sensors, scales and blood pressure monitors via Bluetooth to get a complete picture of health.
The question is whether the likes of VitalPatch can break through its clinical roots and enter the field of use by the average consumer. While the medical profession sees value, they are also concerned about the overload of data. In response, van Haur said: “I think we’re going to get to this point, but what we have to figure out now is that it’s too much information.” We have this technology. It’s always about logistics, which is who cares who pays for it. “
Peter van Haur